top of page
Paresh LinkedIn Photo_edited.jpg
Patrice LinkedIn Photo_edited.jpg
John LinkedIn Photo_edited.jpg

Paresh Soni, CEO

20+ years of executive pharmaceutical experience in Cardio-vascular diseases and MASH that includes Amarin, Alexion, Pfizer and Albireo. Led the NDA submission and approval of Vascepa®, designed and launched the landmark REDUCE-IT study.

Patrice Binay, VP of Chemistry & CMC

32 years of pharmaceutical Fine Chemistry experience. Synthesis and analytical characterization of Active Pharmaceutical Ingredients, Quality auditing, Industrial Transfer. Development of a new class of anti-inflammatory (H4 Receptor).

John M. Burke, Co-Founder

Damion LinkedIn Photo.jpg
Menno LinkedIn Photo_edited.jpg

Inventor of Corvida™ with 46 years Chemical Engineering expertise.

Damion J. Boyer, Co-Founder/COO

6 years experience as CEO of Corvidane. Responsible for initiating Corvidane’s MASH program and forging strategic alliances in the U.S. and Europe, which includes UMC Utrecht and resulted in a non-dilutive subsidy from the Dutch government.

Menno van Burken, VP of Commercial

32 years of global pharmaceutical experience across diverse commercial roles with Pfizer. Lead Cardiovascular and Metabolic therapeutic disease initiatives across R&D, Clinical Development, Medical Affairs, Regulatory and Commercial functions (inlcluding pricing market access, competitive intelligence)

bottom of page